Clinical Trial Detail

NCT ID NCT02077933
Title Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Novartis Pharmaceuticals
Indications

pancreatic endocrine carcinoma

kidney cancer

Advanced Solid Tumor

breast cancer

Therapies

Alpelisib + Everolimus

Alpelisib + Everolimus + Exemestane

Age Groups: senior adult

No variant requirements are available.